Absci is trading at $9.40, up 5.15% in pre-market on October 9, 2026; no confirmed new company announcement explains the move. - Absci closed at $8.94 on October 8. - Recent coverage concerned Phase 2 STORYLINE trial plans outlined in September and discussed October 7, not a clearly new overnight catalyst. - Nasdaq futures and index context was positive, but evidence does not establish it caused the gain. A recent AstraZeneca story appears to describe the previously reported collaboration, not a new October 9 announcement.